Pfizer Inc. proved its ongoing interest in antibody-drug conjugates (ADCs), as well as at least tentative faith in mesothelin as a target, by snatching up Nona Biosciences Inc. for up to $53 million in up-front and near-term cash along with possibly $1.05 billion in milestone payments as the drug advances. Read More
Following the recommendation of its Oncology Drugs Advisory Committee, the U.S. FDA approved U.S. Worldmeds LLC’s eflornithine 192-mg tablets for use as a maintenance therapy in patients with high-risk neuroblastoma. Branded Iwilfin, the specific, irreversible inhibitor of ornithine decarboxylase previously known as DFMO, is expected to be available in the coming weeks. Read More
If the COVID-19 pandemic shocked countries to build self-reliance in biomedical ecosystems, the re-opening of borders in 2023 kickstarted international collaborations to grow major biohubs in Asia. Countries in the Asia Pacific region – including Singapore, China, Japan, Korea and Australia – increasingly drew overseas investors and collaborators, helping each country grow national biotech capabilities and expertise. Read More
The BioWorld Biopharmaceutical Index (BBI) made an upward turn to end November with a 4.37% increase for the year. It has been a dynamic year for BBI, which reached a low point at the end of February (down 3.65%) and peaked at the end of August (up 7.87%). In October, BBI ended the month up 0.98% and outperformed both the Nasdaq Biotechnology Index and the Dow Jones Industrial Average. Read More
Biopharma deals totaled $18.97 billion in November, marking a notable decrease from October’s historic deal value of $44.91 billion. Even still, through the first 11 months of 2023 cumulative deal value reached $194.26 billion, an 18.65% gain over the $163.73 billion recorded in the same period in 2022. Read More
One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee a more vibrant year ahead for the market. Giving all of them hope were technological breakthroughs such as artificial intelligence, game changing weight loss drugs, the surging fascination with ADCs and hope for lower interest rates. But uncertainty looms about the upcoming general election in the U.S. and ground-shifting gene therapies. Read More
You asked and we listened. Now, in addition to the daily news lineup, you can create topic alerts to be delivered directly to your inbox or via an RSS reader. It’s easy to set up. Instructions can be found here: https://www.bioworld.com/featured-feeds. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 1st, Agomab, Bio-Path, Kiromic, Maze, Clearside, Halia, Merck, Mind, Moderna, Reneo, Sellas, Rezolute and Travere. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: ITM Isotope, Merck, Morphogenesis, Tuhura. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbisko, Amgen, Apellis, CV6, Esperion, Kyverna, Mission. Read More
